Gary Herman

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · New England Journal of Medicine · 2017 · 875 citations · Full text

Medicine, Genetics, Molecular Genetics +15

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 519 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 499 citations

Medicine, Endocrinology, Pharmacology +17

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Meagan P. O’Brien, Eduardo Forleo‐Neto, Bret J. Musser et al. · New England Journal of Medicine · 2021 · 480 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17